These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24890314)

  • 1. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
    Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
    Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
    Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
    Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
    Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
    Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
    Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A.
    Giese T; Zeier M; Schemmer P; Uhl W; Schoels M; Dengler T; Buechler M; Meuer S
    Transplantation; 2004 Feb; 77(3):339-44. PubMed ID: 14966405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.
    Kikuchi M; Okuda Y; Ueda Y; Nishioka Y; Uesugi M; Hashimoto E; Takahashi T; Kawai T; Hashi S; Shinke H; Omura T; Yonezawa A; Ito T; Fujimoto Y; Kaido T; Chiba T; Uemoto S; Matsubara K; Masuda S
    Biol Pharm Bull; 2014; 37(3):417-23. PubMed ID: 24369269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients.
    Billing H; Breil T; Schmidt J; Tönshoff B; Schmitt CP; Giese T; Engelmann G
    Pediatr Transplant; 2012 Mar; 16(2):187-94. PubMed ID: 22360403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a.
    Herden U; Kromminga A; Hagel C; Hartleb J; Nashan B; Sterneck M; Fischer L
    Ther Drug Monit; 2011 Apr; 33(2):185-91. PubMed ID: 21383649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Ueda Y; Uemoto S
    Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
    Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
    Trials; 2014 Dec; 15():489. PubMed ID: 25494823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
    Charlton M
    Hepatology; 2011 Jul; 54(1):3-5. PubMed ID: 21710471
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
    Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
    Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient.
    Lemaitre F; Jezequel C; Verdier MC; Dermu M; Boglione-Kerrien C; Boudjema K; Bellissant E
    Transpl Infect Dis; 2015 Feb; 17(1):106-10. PubMed ID: 25573697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
    Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
    Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
    Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
    Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
    Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
    Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.